BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37125473)

  • 21. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Infection of hepatitis C virus in patients with chronic renal failure undergoing hemodialysis therapy and staff members].
    Miyasaka M
    Nihon Jinzo Gakkai Shi; 1991 Oct; 33(10):989-99. PubMed ID: 1722830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
    Maduell F; Belmar L; Ugalde J; Laguno M; Martínez-Rebollar M; Ojeda R; Arias M; Rodas L; Rossi F; Llovet LP; González LN; Mallolas J; Londoño MC
    Gastroenterol Hepatol; 2019 Mar; 42(3):164-170. PubMed ID: 30293914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.
    Gvinjilia L; Baliashvili D; Shadaker S; Averhoff F; Kandelaki L; Kereselidze M; Tsertsvadze T; Chkhartishvili N; Butsashvili M; Metreveli D; Gamkrelidze A; Armstrong PA
    Clin Infect Dis; 2023 Aug; 77(3):405-413. PubMed ID: 37099136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Performance of Algorithms That Use Serial Hepatitis C RNA Tests to Predict Treatment Initiation and Sustained Virological Response Among Patients Infected With Hepatitis C Virus.
    Osinubi A; Harris AM; Vellozzi C; Lom J; Miller L; Millman AJ
    Am J Epidemiol; 2019 Mar; 188(3):555-561. PubMed ID: 30535062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects.
    Isoda H; Oeda S; Takamori A; Sato K; Okada M; Iwane S; Takahashi H; Anzai K; Eguchi Y; Fujimoto K
    Intern Med; 2020 Jan; 59(2):169-174. PubMed ID: 31534084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital.
    Okushin K; Suzuki R; Tsutsumi T; Okamoto K; Ikeuchi K; Kado A; Minatsuki C; Minami-Kobayashi Y; Satoh N; Ikeda M; Harada S; Enooku K; Fujinaga H; Yotsuyanagi H; Koike K; Moriya K
    BMC Infect Dis; 2021 Apr; 21(1):399. PubMed ID: 33931015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
    Nakagawa A; Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Arai T; Hashimoto S; Matsushita Y; Fukuda T; Nakatsuka K; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1329-34. PubMed ID: 25357216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
    Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
    Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Status of Hepatitis C Virus-Infected Maintenance Hemodialysis Patients in Japan.
    Abe T; Oomori S; Obara W
    Ther Apher Dial; 2018 Feb; 22(1):58-60. PubMed ID: 29071791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.